The psychiatric medication history: Context, purpose, and method

Social Work in Mental Health

Volumn 1, Issue 4, 2004, Pages 5-28

  Cohen, David ^a  

^a NONE

Author keywords

Medication history; Psychopharmacology; Social work

Indexed keywords

EID: 33544459542     PISSN: 15332985     EISSN: 15332993     Source Type: Journal    
DOI: 10.1300/J200v01n04_02     Document Type: Article

References (52)

1. Antonuccio, D. O., Burns, D. D., & Danton, W. G. (2002). Antidepressants: A triumph of marketing over science? Treatment and Prevention, 5, article 25. Available on WorldWide Web, http://journals.apa.org/prevention/volume5/ pre0050025c.html.
2. Braslow, J. (1997). Mental ills and bodily cures: Psychiatric treatment in the first half of the twentieth century. Berkeley: University of California Press.
3. Breggin, P. R. (1983). Iatrogenic helplessness in authoritarian psychiatry. In R. F. Morgan (Ed.), The iatrogenics handbook: A critical look at research and practice in the helping professions (pp. 39-51). Toronto: IPI Publishing.
4. Breggin, P.R., & Cohen, D. (1999). Your drug may be your problem: How and why to stop taking psychiatric medications. Cambridge, MA: Perseus.
5. Cohen, D. (1988). Social work and psychotropic drug treatments. Social Service Review, 62, 576-599.
6. Cohen, D. (1997a). A critique of the use of neuroleptic drugs in psychiatry. In S. Fisher & R. G. Greenberg (Eds.), From placebo to panacea: Putting psychiatric drugs to the test (pp. 173-228). New York: Wiley.
7. Cohen, D. (1997b). Psychiatrogenics: Introducing chlorpromazine in psychiatry. Review of Existential Psychology and Psychiatry, 23 (1-2), 206-233.
8. Cohen, D. (2001). How to detoxify from common illusions about psychiatric medications. Ethical Human Sciences and Services, 3, 207-211.
9. Cohen, D. (2002). Research on the drug treatment of schizophrenia: A critical appraisal and implications for social work education. Journal of Social Work Education, 38, 217-239.
10. Cohen, D., Collin, J., Perodeau, G., & McCubbin, M. (2001). Medications as social phenomena. Health: An Interdisciplinary Journal for the Social Study of Health, Illness and Medicine, 5, 441-469.
11. Cohen, D., & Jacobs, D. (2000). A model consent form for psychiatric drug treatment. Journal of Humanistic Psychology, 40, 59-64.
12. Cohen, D., & Karsenty, S. (1998). Representations sociales des effets secondaires des anxiolytiques: Une etude comparative Quebec-France. [Social representations of the side effects of anxiolytic drugs: A comparative Quebec-France study]. Research report submitted to the Research Branch, Ministry of Health & Municipal Affairs, France.
13. Cross, M. (1996). (Ed). Advertising and culture: Theoretical perspectives. Westport, CT: Praeger.
14. Dolnick, E. (1998). Madness on the couch: Blaming the victim in the heyday of psychoanalysis. New York: Simon & Schuster.
15. Fancher, R. T. (1995). Cultures of healing: Correcting the image of American mental health care. San Francisco: Freeman.
16. Farmer, R., & Bentley, K. J. (2002). Social workers as medication facilitators. In K. J. Bentley (Ed.), Social work practice in mental health: Contemporary roles, tasks, and techniques (pp. 211-229). Pacific Grove, CA: Brooks/Cole.
17. Fisher, S., & Greenberg, R. G. (1997). What are we to conclude about psychoactive drugs? In S. Fisher & R. Greenberg (Eds.), From placebo to panacea: Putting psychiatric drugs to the test (pp. 359-384). New York: Wiley.
18. Floersch, J. (2002). Meds, money, and manners: The case management ofsevere mental illness. New York: Columbia University Press.
19. Fortune. (2000). How the industries stack up. Retrieved October 17, 2000, from http://www.fortune.com/indexw.jhtml?channel=artcol.jhtml&doc_id=00001423
20. Gettman, D. A., Ranelli, P. L., & Ried, L.D. (1996). Influence of gender on outcomes of medication-history interviewing. Patient Education and Counseling, 27, 147-160.
21. Gibbs, L., & Gambrill, E. (1999). Critical thinking for social workers: Exercises for the helping professions. Thousand Oaks, CA: Pine Forge Press.
22. Gosden, R., & Beder, S. (2001). Pharmaceutical agenda-setting in mental health policy. Ethical Human Sciences and Services, 3, 147-159.
23. Grinspoon, L., & Hedblom, P. (1975). The speed culture: Amphetamine use and abuse in America. Cambridge, MA: Harvard University Press.
24. Healy, D. (1997). The antidepressant era. Cambridge, MA: Harvard University Press.
25. Healy, D. (2002, February). Problems with antidepressants. Paper presented at the Institute of Psychiatry, London.
26. Hoehn-Saric, R., Lipsey, J. R., & McLeod, D. A. (1990). Apathy and indifference in patients on fluvoxamine and fluoxetine. Journal of Clinical Psychopharmacology, 10, 343-345.
27. Jacobs, D. H., & Cohen, D. (1999). What is really known about psychological alterations produced by psychiatric drugs? International Journal of Risk and Safety in Medicine, 12, 37-47.
28. Jacobs, D. H., & Cohen, D. (In press). Hidden in plain sight: DSM-IV’s rejection of the categorical approach to psychiatric diagnosis. Review of Existential Psychology and Psychiatry.
29. Johnson, A. B. (1990). Out of Bedlam: The truth about deinstitutionalization. New York: Basic Books.
30. Johnson, H. C. (1999). Psyche, synapse, and substance: The role of neurobiology in emotion, behavior, thinking, and addiction for non-scientists. Greenfield, MA: Deerfield Valley.
31. Julien, R. M. (1992). A primer of drug action: A concise, nontechnical guide to the actions, uses, and side effects of psychoactive drugs (6th ed.). New York: Freeman.
32. Kemker, S. S., & Khadivi, A. (1995). Psychiatric education: Learning by assumption. In C. Ross & A. Pam (Eds.), Pseudoscience in biological psychiatry: Blaming the body (pp. 241-253). New York: Wiley.
33. Kirsch, I., Moore, T. J., Scoboria, A., & Nicholls, S. N. (2002). The Emperor’s new drugs: An analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prevention & Treatment, 5, article 23. Available on World Wide Web: http://journals.apa.org/prevention/volume5/toc-jul15-02.htm
34. Klungel, O. H., de Boer, A., Paes, A. H. P., Herings, R. M. C., Seidell, J. C., & Bakker, A. (2000). Influence of question structure on the recall of self-reported drug use. Journal of Clinical Epidemiology, 53, 273-277.
35. Kurth, J. (2002, December 12). Ritalin is safe-and it works. The Detroit Free Press. Retrieved December 12, 2002, from http://www.detnews.com
36. Lau, H. S., Florax, C., Porsius, A. J., & de Boer, A. (2000). The completeness of medication histories in hospital medical records of patients admitted to general internal medicine wards. British Journal of Clinical Pharmacology, 49, 597-603.
37. Luhrman, T. M. (2001). Of two minds: The growing disorder in American psychiatry. New York: Knopf.
38. Othmer, E., & Othmer, S. C. (2002). The clinical interview using DSM-IV-TR. Fundamentals. Washington, D.C. & London: American Psychiatric Press.
39. Paul, R. W., & Elder, L. (2002). Critical thinking: Tools for taking charge of your professional and personal life. Upper Saddle River, NJ: Financial Times/Prentice Hall.
40. Relman, A., & Angell, M. (2002, December 16). America’s other drug problem: How the drug industry distorts medicine and politics. The New Republic. Retrieved December 19, 2002 from http://www.tnr.com
41. Research Triangle Institute. (2002). Screening for depression: Systematic evidence review. Rockville, MD: Agency for Health Care Quality and Research.
42. Safer, D. J. (2002). Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. Journal of Nervous and Mental Disease, 190, 583-592.
43. Schatzberg, A. F., & Nemeroff, C. (Eds.). (1998). The American Psychiatric Press textbook of psychopharmacology (2nd ed.). Washington, DC: American Psychiatric Press.
44. Schulman, K. A., Seils, D. M., Timbie, J. W., Sugarman, J., Dame, L. A., Weinfurt, K. P., Mark, D. B., & Califf, R. M. (2002). A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. New England Journal of Medicine, 347, 1335-1341.
45. Smith, D. (2001). On the incompatibility of the biological and empathic-relational model. Ethical Human Sciences and Services, 3, 47-52.
46. Thornley, B., & Adams, C. (1998). Content and quality of 2000 controlled trials in schizophrenia over 50 years. British Medical Journal, 317, 1181-1184.
47. Torrey, E. F. (1992). Freudian fraud: The malignant impact of Freud’s theory on American thought and culture. New York: HarperCollins.
48. Tucker, G. (1998). Putting DSM-IV in perspective. American Journal of Psychiatry, 155, 159-161.
49. Vastag, B. (2001). Pay attention: Ritalin acts much like cocaine. JAMA, 286, 905-906.
50. Whitaker, R. (2002). Mad in America: Bad science, bad medicine, and the enduring mistreatment of the mentally ill. Cambridge, MA: Perseus Publishing.
51. Wyatt, R. J. (1998). Practical psychiatric practice: Forms and protocols for clinical use (2nd ed.). Washington, D.C. & London: American Psychiatric Press.
52. Zito, J. M., Safer, D. J., dosReis, S., Gardner, J. F., Magder, L., Soeken, K., Boles, M., Lynch, F., & Riddle, M. (2003). Psychotropic practice patterns for youth: A 10-year perspective. Archives of Pediatric and Adolescent Medicine, 157, 17-25.